- Home
- LUCY vs OGEN Comparison
LUCY vs OGEN Comparison
Compare LUCY & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | OGEN |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 2.7M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | LUCY | OGEN |
|---|---|---|
| Price | $0.98 | $0.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 78.6K | 40.9K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $175.92 | N/A |
| Revenue Next Year | $205.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $0.11 |
| 52 Week High | $3.54 | $9.16 |
Technical Indicators
Market Signals| Indicator | LUCY | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.86 | 47.51 |
| Support Level | N/A | $0.56 |
| Resistance Level | $1.17 | $0.66 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 57.67 | 44.49 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About OGEN Oragenics Inc.
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.